PATENT COOPERATION TREATY

Trom the NTERNATIONAL PRELIMINARY EXAM To: MICHAEL J. MALLIE BLAKELY, SOKOLOFF, TAYLOI 12400 WILSHIRE BOULEVARD 7TH FLOOR LOS ANGELES CA	APR O	2001 a ZAFMAN Date of Mailing (day/month/year)	PCT WRITTEN OPINIONOM (PCT Rule 66) STATUS DB-LA 0 4 APR 2001	
Applicant's or agent's file reference		REPLY DUE	within TWO months from the above date of mailing	
42390.P6874 9(4	International filing date	(day/month/year)	Priority date (day/month/year)	
International application No.		(ua), morror, y	08 JULY 1999	
PCT/US00/17664	26 JUNE 2000		00 3021 1772	
International Patent Classification (IPC) IPC(7): G06F 9/46 and US Cl.: 709	or both national classific 9/102 712/245	ation and IPC		
Applicant Intel Corporation				
			rnational Preliminary Examining Authority.	
1. This written opinion is the first	(first, etc.)	drawn by this filter	mational Foliances y 2.	
2. This opinion contains indications re	elating to the following it	ems:	t	
			\	
I X Basis of the opinion				
II Priority			4: 1325	
III Non-establishment of	of opinion with regard to	novelty, inventive	step or industrial applicability	
L 1 of with of im				
Lack of unity of five	COLUMN TO THE PARTY OF THE PART	sh -agged to novel	ty inventive step or industrial applicability;	
V X Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
VI Certain documents	cited			
VII Certain defects in t	he international application	on		
VII Certain defects in the international application VIII Certain observations on the international application				
3. The applicant is hereby invited to reply to this opinion.				
When? See the time limit indicated above. The applicant may, before the expiration of that which the same ten extension see Bule 66.2(d).				
How? By submitting a written reply, accompanied, where appropriate, by amendments, according to kine 66.5. For the form and the language of the amendments, see Rules 66.8 and 66.9.				
Also For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.				
For an informal communication with the examiner, see Rule 60.0. If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.				
4. The final date by which the interexamination report must be esta				
Name and mailing address of the IPI	EA/US	Authorized of	micer lagger Harrot	
Commissioner of Patents and Tr	ademarks	LARRY D	OONAGHUE	
Box PCT Washington, D.C. 20231		Telephone N		
Facsimile No. (703) 305-3230		Telephone 14	V. (1.50) 555 1	

WRITTEN OPINION

International application No.	
PCT/US00/17664	

1. With regard to the elements of the international application:* X	
the description: pages 1-33	
the description: pages 1-33	
pages 1-33	
the claims: pages 34-44 , as original pages NONE , filed with the letter of X	y filed
the claims: pages 34-44 , as original pages NONE , filed with the letter of pages NONE , as amended (together with any statement) under An pages NONE , filed with the letter of filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages NONE , filed with the letter of as original pages of NONE , filed with the letter of as original pages of the language, all the elements marked above were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b) the language of publication of the international application (under Rule 48.3(b)) the language of the translation furnished for the purposes of international preliminary examination (under Rule drawn on the basis of the sequence listing: contained in the international application in printed form filed together with the international application in computer readable form furnished subsequently to this Authority in written form.	lemand
the claims: pages	
pages NONE , as amended (together with any statement) under Al pages NONE , filed with the letter of X the drawings:	
pages NONE , as amended (together with any statement) under Al pages NONE , filed with the letter of X the drawings:	1 61 -
pages NONE , as amended (together with any statement) that he pages NONE , filed with the letter of	ny med
pages NONE , filed with the letter of	lemand
the drawings: pages 1-13 , as original pages NONE , filed with the letter of , filed with the pages NONE , filed with the letter of X	icilianu
pages NONE , filed with the letter of , filed with the pages NONE , filed with the letter of , filed with the pages NONE , filed with the letter of , as original pages NONE , filed with the letter of , as original pages NONE , filed with the letter of , filed with the pages NONE , filed with the letter of 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b) the language of publication of the international application (under Rule 48.3(b)). In the language of the translation furnished for the purposes of international preliminary examination (under Rule or 55.3). 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: Contained in the international application in printed form. If filed together with the international application in computer readable form. If furnished subsequently to this Authority in written form.	
pages 1-13	
pages NONE , filed with the letter of	ly filed
X the sequence listing part of the description: pages NONE	201110110
the sequence listing part of the description: pages NONE pages NONE N	
pages NONE , as original none pages NONE , filed with the letter of, filed with the pages NONE , filed with the letter of, filed with the letter of 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b) the language of publication of the international application (under Rule 48.3(b)) the language of the translation furnished for the purposes of international preliminary examination (under Rule 755.3). 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: contained in the international application in printed form filed together with the international application in computer readable form furnished subsequently to this Authority in written form.	
pages NONE , as original none pages NONE , filed with the letter of, filed with the pages NONE , filed with the letter of, filed with the letter of 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b) the language of publication of the international application (under Rule 48.3(b)) the language of the translation furnished for the purposes of international preliminary examination (under Rule 755.3). 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: contained in the international application in printed form filed together with the international application in computer readable form furnished subsequently to this Authority in written form.	ly filed
pages NONE , filed with the letter of	demand
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b)) the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rule 75.3). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.	
 With regard to the language, all the elements marked above were available or furnished to this Authority in the language the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rule or 55.3). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. 	
or 55.3). 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written drawn on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.	
drawn on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.	
contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.	- ⊾muvıt Wd
filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.	
furnished subsequently to this Authority in written form.	
т при	
furnished subsequently to this Authority in computer readable form.	re in the
The statement that the subsequently furnished written sequence listing does not go beyond the disclosu international application as filed has been furnished.	
The statement that the information recorded in computer readable form is identical to the writen sequence I been furnished.	omik uas
4. X The amendments have resulted in the cancellation of:	
X the description, pages NONE	
the description, pages	
the claims, 140s.	
1 I the drawings, should be a superior of the	idered to g
5. This opinion has been drawn as if (some of) the amendments had not been made, since they have been cons beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).	
* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are in this opinion as "originally filed".	referred to

International application No. PCT/US00/17664

	WRITTEN OPINIO	ION (ii) with regard to novelty, inventive step or industrial apparent statement	plicability;
v.	Reasoned statement under Rule 66.2(a) citations and explanations supporting	such states.	
1.	tetament	Claims 31-43 and 50 Claims 1-30 and 44-49	NO YES NO
	Inventive Step (IS)	Claims 31, and 42-43 Claims 1-30, 32-41 and 44-50	YES
	Industrial Applicability (IA)	Claims 1-50 Claims NONE	NO
1		n skanhagen et al. (V	NO 99/21082).

NONE

Claims 1-30 and 44-49 lack novelty under PCT Article 33(2) as being anticipated by Borkenhagen et al. (WO 99/21082). 2. citations and explanations

Borkenhagen et al. taught assigning priority o a first thread for a first duration, determining when the first duration has expired and assigning processing priority to a second thread (page 9, lines 5-25).

Borkenhagen et al. taught setting a priority level (page 19, lines 10-12), using priority bits (page 19, lines 10-12), setting the priority time period, loading a priority counter, keeping track of the duration and checking the elapsed time (page 12), the priority time period, loading a priority counter, keeping track of the duration and checking the elapsed time (page 2) delays 2 100

Claims 32-41 and 50 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied in the Claims 32-41 and 30 lack an inventive step under PC1 Article 33(3) as being obvious over the prior art as applied in the immediately preceding paragraph and further in view of Steere et al. (A Feedback-driven proportion Allocator for Real-Rate 37, claims 8-10).

Borkenhagen et al. did not expressly detail the reprogramming of the duration period, based on the internal measurements of the system progress. Steere et al. taught the implementation and the benefit of based on the internal Scheduling).

Claims 31 and 42-43 the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the measurements of the system progress (pages 145 and 156). increasing the first duration a predetermined amount on the conditions of lack of progress the last time the thread had increasing the 111st duration a predetermined amount on the conditions of lack of progress the last time the threat had processing priority and the processing priority having been switched and the predetermined restart period is set in response

claims 31 and 42 duration a predetermined that increasing the first duration a predetermined that increasing the first duration a predetermined that increasing the first duration a predetermined that is a switched and the processing priority having been switched and the processing priority and the processing priority having been switched and the processing priority having been	
NEW CITATIONS	

WRITTEN OPINION

International application No.

PCT/US00/17664

Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient)				
Continuation of: Boxes I - VIII	Sheet 10			
TIME LIMIT: The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.				